Hepatocellular Carcinoma: Self‐Activated Cascade‐Responsive Sorafenib and USP22 shRNA Co‐Delivery System for Synergetic Hepatocellular Carcinoma Therapy (Adv. Sci. 5/2021)

Shengjun Xu; Sunbin Ling; Qiaonan Shan; Qianwei Ye; Qifan Zhan; Guangjiang Jiang; Jianyong Zhuo; Binhua Pan; Xue Wen; Tingting Feng; Haohao Lu; Xuyong Wei; Haiyang Xie; Shusen Zheng; Jiajia Xiang; Youqing Shen; Xiao Xu

doi:10.1002/advs.202170022

journal article·2021-03Open access

Hepatocellular Carcinoma: Self‐Activated Cascade‐Responsive Sorafenib and USP22 shRNA Co‐Delivery System for Synergetic Hepatocellular Carcinoma Therapy (Adv. Sci. 5/2021)

Shengjun Xu, Sunbin Ling, Qiaonan Shan, Qianwei Ye, Qifan Zhan, Guangjiang Jiang, Jianyong Zhuo, Binhua Pan, Xue Wen, Tingting Feng, Haohao Lu, Xuyong Wei, Haiyang Xie, Shusen Zheng, Jiajia Xiang, Youqing Shen, Xiao Xu

Advanced Science· Volume 8· Issue 5

Publisher page Open full text

Source abstract

Abstract

Resistance to sorafenib remains one of the biggest concerns for hepatocellular carcinoma treatment. In article number 2003042, Xiao Xu, Jiajia Xiang, and co‐workers developed a self‐activated sorafenib and USP22 shRNA codelivery nanoplatform (Gal‐SLP) to reverse cancer stemness and sensitive cancer cells to sorafenib. Gal‐SLP releases USP22 shRNA efficiently and enhances the intracellular sorafenib accumulation in cancer cells. Gal‐SLP exhibits potent antitumor efficiency in a sorafenibinsensitive patient‐derived xenograft (PDX) model. [Image: see text]

Source: openalex_inverted_index · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Research and Treatments · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References

Reference metadata was not supplied for this record.